June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Novel Minimally-Invasive Episcleral Brachytherapy for the Treatment of Neovascular Age-Related Macular Degeneration (nAMD): Results of a Twelve Month Prospective Phase I Safety and Tolerability Evaluation
Author Affiliations & Notes
  • Kamaljit Balaggan
    Department of Genetics, Institute of Ophthalmology, London, United Kingdom
    Vitreoretinal Service, Moorfields Eye Hospital, London, United Kingdom
  • Reid Schindler
    Ophthalmology, University of Arizona, Tucson, AZ
  • Leonard Joffe
    Ophthalmology, University of Arizona, Tucson, AZ
  • Praveen Patel
    Medical Retina Service, Moorfields Eye Hospital, London, United Kingdom
  • Baldassrre Stea
    Radiation Oncology, University of Arizona, Tucson, AZ
  • Adnan Tufail
    Medical Retina Service, Moorfields Eye Hospital, London, United Kingdom
  • Laurence Marsteller
    SalutarisMD, Tucson, AZ
  • Footnotes
    Commercial Relationships Kamaljit Balaggan, None; Reid Schindler, SalutarisMD (F), SalutarisMD (I), SalutarisMD (C), SalutarisMD (S); Leonard Joffe, SalutarisMD (F), SalutarisMD (I), SalutarisMD (C), SalutarisMD (S); Praveen Patel, Allergan (R), Bayer (C), Novartis UK (C), Heidelberg UK (R), Topcon UK (R), Thrombogenics (C); Baldassrre Stea, SalutarisMD (C); Adnan Tufail, Allergan (C), Bayer (C), GSK (C), Oculogics (C), Pfizer (C), Thrombogenics (C), Amakem (C), Heidelberg Engineering (R), Novarits/Alcon (C), Sanofi/Genzyme (C); Laurence Marsteller, SalutarisMD (I), SalutarisMD (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3787. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kamaljit Balaggan, Reid Schindler, Leonard Joffe, Praveen Patel, Baldassrre Stea, Adnan Tufail, Laurence Marsteller; Novel Minimally-Invasive Episcleral Brachytherapy for the Treatment of Neovascular Age-Related Macular Degeneration (nAMD): Results of a Twelve Month Prospective Phase I Safety and Tolerability Evaluation. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3787. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To evaluate the safety and feasibility of a novel episcleral brachytherapy device (SMD-1) for nAMD. Although anti-VEGF treatments have revolutionised the management of nAMD, they fail to significantly improve vision in the majority of patients, with some patients demonstrating no response to treatment. As neovascular regression is not achieved, many patients will likely require lifelong and often frequent invasive intravitreal injections. Radiation has multiple angiostatic properties which could address these issues, and has recently been evaluated using both vitrectomy and stereotactic external beam delivery methods. These approaches, however, are either invasive with predictable adverse effects or necessitate large complex expensive devices. A locally-delivered non-penetrating brachytherapy approach could overcome these limitations

 
Methods
 

6 patients received 24Gy radiation over 5.5 minutes directly to the macular CNV by positioning the SMD-1 brachytherapy probe adjacent to the macular sclera via a subtenon retrobulbar approach. The probe was then removed. Patients also received concomitant anti-VEGF injections with further readministration as-needed. Adverse effects and changes in BCVA and macular thickness were evaluated monthly

 
Results
 

The procedure was readily performed and was well tolerated with no serious adverse effects. At 3 months, all patients experienced increases in BCVA (mean +19 ETDRS letters). By 12 months, 3 patients continued to demonstrate improved or stabilised BCVA (mean +7 letters), 2 of whom required no further anti-VEGF injections during follow-up. All patients demonstrated reduced macular thickness compared with baseline. Three patients demonstrated reductions in BCVA

 
Conclusions
 

This prospective study supports the safety and tolerability of this novel device, and its further evaluation in planned larger phase I/II trials

 
 
The SMD-1 Episcleral Brachytherapy for nAMD Device
 
The SMD-1 Episcleral Brachytherapy for nAMD Device
 
Keywords: 412 age-related macular degeneration • 671 radiation therapy • 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×